Jason A. Okazaki, born on October 1, 1976, is the CEO of Assembly Biosciences, Inc., a biotech company focused on innovative treatments. He took over as CEO on January 1, 2023, after serving as President and Chief Operating Officer. His...

Jason A. Okazaki, born on October 1, 1976, is the CEO of Assembly Biosciences, Inc., a biotech company focused on innovative treatments. He took over as CEO on January 1, 2023, after serving as President and Chief Operating Officer. His journey with Assembly began in 2020, and he quickly rose through the ranks, starting as the Chief Legal and Business Officer. With a strong foundation in business operations, Okazaki has been pivotal in navigating the company through significant transitions, including a strategic restructuring in 2022. In 2023, he earned a total compensation of $1,373,710, which included a base salary of $600,000 and performance bonuses, reflecting his alignment with the company’s goals. Before his rise to the top, his insider trading activity showed substantial financial commitment to Assembly, peaking at $1.24 million in value during mid-2020. This pattern indicates his confidence in the company’s prospects and commitment to its long-term vision. Beyond numbers, Okazaki's leadership style is about resilience and strategic growth in a challenging biotech environment, making him a key figure in the industry.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Assembly Biosciences CEOs

A

Jason A. Okazaki

CEO of Assembly Biosciences

Field of Expertise

Business & Management - Operations

Sector of Economy

Healthcare

Born

October 1, 1976 - 48 years ago

CEO of Assembly Biosciences for

2 years 5 months (Jan 2023 - Present)

Previous Experience

Held positions of increasing responsibility at the Company since 2020, including Chief Legal and Business Officer and Chief Operating Officer.

Rivals

Competitors/colleagues of Jason A. Okazaki

Holdings

See how much did Jason A. Okazaki make over time.

Jason A. Okazaki has shown a consistent pattern of robust insider trading activity since joining Assembly Biosciences in March 2020. His trading peaked in July 2020 with transactions valued at $1.24 million, indicating a strong belief in the future of...

Jason A. Okazaki has shown a consistent pattern of robust insider trading activity since joining Assembly Biosciences in March 2020. His trading peaked in July 2020 with transactions valued at $1.24 million, indicating a strong belief in the future of the company. Over the years, his trading values fluctuated, reflecting varying confidence levels, but they notably decreased between 2021 and 2022, suggesting a strategic approach to timing in the volatile biotech industry. As of 2023, his trades have become more measured, aligning with his new role as CEO, where he is now focused on longer-term strategic goals rather than short-term gains. In total, his trades from 2020 until now have amassed several million dollars, underscoring his significant financial commitment to Assembly. The value of his holdings indicates both risk and reward, particularly given the company's focus on groundbreaking treatments that could change the landscape of biotech.

Mar 18, 2025

A

shares

ASMB @ $11.26

Total Stock Sold

$564.09K

ASMB

$564.09K

6,809.75 ASMB shares

What if they kept their stock?

If Jason A. Okazaki didn't sell their stock, today they would have:
Extra ASMB6,809.75 shares worth $1.74M.
This is 208.27% and $1.17M more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Jason A. Okazaki.

ASMB

$13.96K

ASMB at $14.23/share

Aug 2, 2024

Sale

ASMB

$8.20K

ASMB at $14.93/share

May 23, 2024

Sale

ASMB

$19.94K

ASMB at $12.71/share

Apr 29, 2024

Sale

ASMB

4,166 shares

ASMB

Apr 29, 2024

Received

ASMB

$4.63K

ASMB at $13.07/share

Mar 29, 2024

Sale

ASMB

$5.05K

ASMB at $12.87/share

Mar 27, 2024

Sale

ASMB

$1.88K

ASMB at $0.80/share

Oct 2, 2023

Sale

ASMB

12,500 shares

ASMB

Oct 2, 2023

Received

ASMB

$12.87K

ASMB at $1.09/share

Aug 2, 2023

Sale

ASMB

50,000 shares

ASMB

Jun 22, 2023

Received

Compensation History

See how much did Jason A. Okazaki make over time.

In 2023, Jason A. Okazaki's total compensation at Assembly Biosciences was $1,373,710. This included a base salary of $600,000, complemented by a performance-based bonus of $453,600. His bonus reflects the successful achievement of company-wide goals during a pivotal time for the firm. Additionally, Okazaki received $306,100 from vested stock options granted, highlighting his alignment with shareholders' interests. His package is structured to motivate high performance while maintaining a competitive level to attract and retain top talent. Despite the challenges faced in the biotech sector, his compensation shows the company's commitment to rewarding leadership that drives innovation and strategic growth.

Year

2023

Total Compensation

$1.37M

Salary

$600.00K

Board Justification

Provide competitive overall compensation that attracts, retains and motivates superior performers, with a focus on aligning compensation with company performance and stockholder interests.

Bonus

$453.60K

Board Justification

Annual performance-based cash bonuses based on the achievement of Company-wide and individual performance goals.

Other

$14.01K

Board Justification

401(k) matching contributions and premiums paid for group term life insurance coverage greater than $50,000.

Restricted Stock

$306.10K(39.17K Stock options)

Board Justification

Stock options granted in 2023 that vested during the year.

Performance Metrics

Achievement of significant pre-set, objective Company-wide goals weighted to reflect their relative importance to the achievement of our goals.

Other Assembly Biosciences CEOs

Here are other CEOs of Assembly Biosciences

John G. McHutchison, A.O., M.D.

Ex-CEO of Assembly Biosciences

January 2019 - December 2022